You're on the list.
The DexaFit Signal lands quarterly. Check your inbox for a confirmation.
Clinical Body Composition Research

The measurement
layer. Decoded.

Research that changes how you train, eat, age, and treat — built on the largest clinical-grade body composition and metabolic dataset in the world.

What the data shows
0%

of women on GLP-1 medications lose clinically significant lean mass — 1.6× the rate observed in men

Age 0

is when bone mineral density begins its measurable decline in women — a full decade before most screening guidelines recommend testing

0%

of adults with a "normal" BMI are metabolically obese on DEXA — carrying 1.4× higher cardiometabolic disease prevalence

Reference Data

Body fat percentage — population distribution by age and sex

Excellent
Good
Fair
Needs Focus

Derived from hundreds of thousands of clinical-grade DEXA assessments. DexaFit Research, 2026.

Latest
Reference GuideBody Composition
How to Read a DEXA Scan Report
DexaFit Research
Original ResearchMetabolic Health
Visceral Fat — Normal, Elevated, and High-Risk Ranges
DexaFit Research
Original ResearchWeight Loss & GLP-1
GLP-1 Medications and Body Composition — What the Data Shows
DexaFit Research
Data NoteBone Health
GE Lunar vs Hologic — Why Your T-Scores Don't Match
DexaFit Research
CuratedPerformance & Longevity
Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality
JAMA Network Open · Mandsager et al.
Topic Collections
Body Composition
Reference ranges, testing, interpretation
4
Weight Loss & GLP-1
Pharmacological interventions & trade-offs
4
Bone Health
T-scores, screening, cross-manufacturer data
3
Metabolic Health
Visceral fat, cardiometabolic risk, TOFI
3
Performance & Longevity
VO₂ Max, endurance, metabolic flexibility
3
Quarterly Publication

The DexaFit Signal

Stay on top of what the data reveals in body composition, longevity, weight loss, and metabolic health — curated with the largest real-world dataset in the field.

Q1 2026 Issue Now Available
Quarterly delivery. No spam. Unsubscribe anytime.
Preview Q1 2026 issue →

Tweaks

Visual Variant